| Ytd | -23.23% | |
| 1y | -30.22% |
| Open | 6.51 | Prev Close | 6.61 | Low | 6.26 | High | 6.63 | Mkt Cap | 389.32M |
| Vol | 1.08M | Avg Vol | 1.19M | EPS | -4.25 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 4.94 | 200-d Avg | 5.98 | 1yr Est | 0.00 |
HELP News
Canaccord Genuity analyst Sumant Kulkarni maintains Helus Pharma (NASDAQ:HELP) with a Buy and low
Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(0.85) per share which beat the analyst con
- Recently closed $50 million underwritten offering reinforces strong institutional investor convict
Cybin operates as Helus Pharma, which is a clinical-stage biotech built around deuterated serotonerg
Issued on behalf of Helus Pharma™ Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial opera
Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday'
NEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP)
- APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorde